English | Español

Phrma
+ Pharmaceuticals
Patient Daily | Aug 21, 2025

PhRMA director of public affairs on 340B rebate model: "Positive first step toward addressing hospital abuse of the 340B program
+ Pharmaceuticals
Patient Daily | Aug 14, 2025

PhRMA COO on 340B: 'Hidden tax on patients, taxpayers & employers'
Patient Daily | Jul 28, 2025

Head of Regulatory Affairs at 2San: ‘A multibillion-dollar clash is brewing over the 340B drug discount program’
+ Pharmaceuticals
Patient Daily | Jul 22, 2025

Deputy VP of Public Affairs of PhRMA: 'It's time for Congress to fix the 340B Drug Pricing Program'
+ Pharmaceuticals
Patient Daily | Jul 10, 2025

PhRMA Executive VP: ‘State policymakers can lead the way and must address 340B abuse and protect patients from PBMs'
+ Pharmaceuticals
Patient Daily | Jun 30, 2025

PhRMA public affairs senior director on 340B program: 'PBMs took $140 billion in rebates and fees, driving up American medicine costs'
+ Pharmaceuticals
Patient Daily | Jun 23, 2025

PhRMA says patients in the U.S. face higher prescription costs due to 340B program
+ Pharmaceuticals
Patient Daily | Jun 9, 2025

Director of Public Affairs of PhRMA: ‘There is also evidence that 340B is harming state and federal budgets’

Trending
+ Pharmaceuticals
Patient Daily | Aug 4, 2026

Merck reports mixed results for tulisokibart in recent clinical trials and financial update
+ Pharmaceuticals
Patient Daily | Aug 6, 2026

FDA approves Replimune’s melanoma drug Tudriqev after advisory committee debate
+ Regulatory
M. R. Armstrong | Aug 4, 2026

Public Policy Solutions on 340B: 'The program has enriched big hospital execs'
+ Pharmaceuticals
Patient Daily | Aug 5, 2026

Bristol Myers Squibb and AstraZeneca reportedly in merger talks amid industry changes